Flory T Muanda1,2, Odile Sheehy2, Anick Bérard1,2. 1. Faculty of Pharmacy, University of Montreal, 2900 Edouard Montpetit, Montréal, Québec, Canada, H3T 1J4. 2. Research Center, CHU Sainte-Justine, 3175, Côte-Sainte-Catherine, Montréal, Québec, Canada, H3T 1C5.
Abstract
AIMS: Data available on the fetal safety of trimethoprim-sulfamethoxazole (TMP-SMX) exposure during pregnancy remains scarce and inconclusive. A previous study assessing the link between TMP-SMX exposure during pregnancy and the risk of spontaneous abortion (SA) did not control for protopathic bias and indication bias. METHODS: We conducted a nested control study (n = 77 429 pregnancies including 7039 cases of SA and 70 390 controls) within the Quebec Pregnancy Cohort. For each case of SA, we selected 10 controls at the index date that were matched on gestational age and year of pregnancy. TMP-SMX exposure was defined as either having filled at least one prescription between the first day of gestation (1DG) and the index date, or as having filled a prescription before pregnancy but with a duration overlapping the 1DG (102 pregnancies exposed to TMP-SMX, including 25 cases of SA and 77 controls). RESULTS: Adjusting for potential confounders, TMP-SMX exposure was associated with an increased risk of SA (AOR 2.94, 95% C 1.89-4.57, 25 exposed cases). Similar results were found after controlling for indication bias and protopathic bias. CONCLUSION: Given that this drug is widely use in HIV patients to prevent opportunistic infections and malaria, there is an urgent need to identify potential data sources in Africa for analysis of early pregnancy exposure to TMP-SMX.
AIMS: Data available on the fetal safety of trimethoprim-sulfamethoxazole (TMP-SMX) exposure during pregnancy remains scarce and inconclusive. A previous study assessing the link between TMP-SMX exposure during pregnancy and the risk of spontaneous abortion (SA) did not control for protopathic bias and indication bias. METHODS: We conducted a nested control study (n = 77 429 pregnancies including 7039 cases of SA and 70 390 controls) within the Quebec Pregnancy Cohort. For each case of SA, we selected 10 controls at the index date that were matched on gestational age and year of pregnancy. TMP-SMX exposure was defined as either having filled at least one prescription between the first day of gestation (1DG) and the index date, or as having filled a prescription before pregnancy but with a duration overlapping the 1DG (102 pregnancies exposed to TMP-SMX, including 25 cases of SA and 77 controls). RESULTS: Adjusting for potential confounders, TMP-SMX exposure was associated with an increased risk of SA (AOR 2.94, 95% C 1.89-4.57, 25 exposed cases). Similar results were found after controlling for indication bias and protopathic bias. CONCLUSION: Given that this drug is widely use in HIVpatients to prevent opportunistic infections and malaria, there is an urgent need to identify potential data sources in Africa for analysis of early pregnancy exposure to TMP-SMX.
Authors: E M Jungmann; D Mercey; A DeRuiter; S Edwards; S Donoghue; T Booth; D Mohan; H Lyall; G P Taylor Journal: Sex Transm Infect Date: 2001-12 Impact factor: 3.519
Authors: Craig Hansen; Susan E Andrade; Heather Freiman; Sascha Dublin; Katie Haffenreffer; William O Cooper; T Craig Cheetham; Sengwee Toh; De-Kun Li; Marsha A Raebel; Jennifer L Kuntz; Nancy Perrin; A Gabriela Rosales; Shelley Carter; Pamala A Pawloski; Elizabeth M Maloney; David J Graham; Leyla Sahin; Pamela E Scott; John Yap; Robert Davis Journal: Pharmacoepidemiol Drug Saf Date: 2015-11-24 Impact factor: 2.890
Authors: Holly Michelle Crowe; Amelia Kent Wesselink; Lauren Anne Wise; Tanran R Wang; Charles Robert Horsburgh; Ellen Margrethe Mikkelsen; Elizabeth Elliott Hatch Journal: Hum Reprod Date: 2021-09-18 Impact factor: 6.353